Brokerages Set Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) PT at $17.25

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $17.25.

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st.

Insider Transactions at Aurinia Pharmaceuticals

In related news, Director Kevin Tang acquired 516,439 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $13.99 per share, for a total transaction of $7,224,981.61. Following the transaction, the director directly owned 11,845,939 shares of the company’s stock, valued at $165,724,686.61. This trade represents a 4.56% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 12.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 1,318 shares during the period. MML Investors Services LLC boosted its position in Aurinia Pharmaceuticals by 12.7% during the 4th quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 1,765 shares during the period. BOK Financial Private Wealth Inc. acquired a new position in Aurinia Pharmaceuticals during the 4th quarter worth $32,000. Concurrent Investment Advisors LLC boosted its position in Aurinia Pharmaceuticals by 7.8% during the 4th quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock worth $483,000 after acquiring an additional 2,200 shares during the period. Finally, CWM LLC boosted its position in Aurinia Pharmaceuticals by 15.5% during the 4th quarter. CWM LLC now owns 16,543 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 2,225 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $15.76 on Monday. Aurinia Pharmaceuticals has a 12-month low of $7.28 and a 12-month high of $16.54. The firm has a market capitalization of $2.10 billion, a P/E ratio of 7.58 and a beta of 1.51. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.25 and a quick ratio of 4.76. The business has a 50 day simple moving average of $14.64 and a 200 day simple moving average of $14.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $1.32. Aurinia Pharmaceuticals had a return on equity of 27.47% and a net margin of 101.46%.The business had revenue of $77.11 million during the quarter, compared to analyst estimates of $74.70 million. Equities research analysts predict that Aurinia Pharmaceuticals will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.